0001209191-23-025720.txt : 20230426 0001209191-23-025720.hdr.sgml : 20230426 20230426171914 ACCESSION NUMBER: 0001209191-23-025720 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230424 FILED AS OF DATE: 20230426 DATE AS OF CHANGE: 20230426 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DOBMEIER ERIC CENTRAL INDEX KEY: 0001202785 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 23850859 MAIL ADDRESS: STREET 1: C/O SAETTLE GENETICS INC STREET 2: 21823 30TH DRIVE SE CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-24 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001202785 DOBMEIER ERIC C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98109 1 1 0 0 President, CEO 0 Common Stock 2023-04-24 4 M 0 25000 0.42 A 326138 D Common Stock 2023-04-24 4 S 0 23800 21.5768 D 302338 D Common Stock 2023-04-24 4 S 0 1200 22.2592 A 301138 D Stock Option (Right to Buy) 0.42 2023-04-24 4 M 0 25000 0.00 D 2030-03-17 Common Stock 25000 313555 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated December 22, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2023-04-26